Related Experiment Video
Updated: May 23, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Statin and Immune-Related Cardiovascular Events in Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
Junmin Song1, Kuan-Yu Chi1, Hyein Jeon2
1Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Statins may reduce major adverse cardiovascular events (MACE) and all-cause mortality in lung cancer patients undergoing immune checkpoint inhibitors (ICIs). This study found no increased risk of serious immune-related adverse events with statin use.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) are vital in lung cancer therapy but carry cardiotoxicity risks.
- Investigating statins' potential to mitigate cardiovascular risks associated with ICIs in lung cancer patients.
More Related Videos
Related Concept Videos
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

